Ibrutinib for chronic lymphocytic leukemia: international experience from a named patient program

• Peter Hillmen,
• Joris Diels,
• Nollaig Healy,
• Wafae Iraqi,
• Johan Aschan,
• Mark Wildgust

Affiliations

Peter Hillmen

The Leeds Teaching Hospitals, St. James Institute of Oncology, Leeds, UK

Joris Diels

Janssen EU HEMAR Statistics & Modeling, Beerse, Belgium

Nollaig Healy

Janssen-Cilag EMEA Medical Affairs, Dublin, Ireland

Wafae Iraqi

Janssen Pharmaceuticals, Paris, France

Johan Aschan

Janssen-Cilag EMEA Medical Affairs, Sollentuna, Sweden

Mark Wildgust

Janssen Research & Development, Raritan, NJ, USA